A Phase 3, Randomized, Open-Label Study of Lopinavir/Ritonavir Tablets 800/200 mg Once-Daily Versus 400/100 mg Twice-Daily When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced, HIV-1 Infected Subjects.

Trial Profile

A Phase 3, Randomized, Open-Label Study of Lopinavir/Ritonavir Tablets 800/200 mg Once-Daily Versus 400/100 mg Twice-Daily When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced, HIV-1 Infected Subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Apr 2010 The FDA has approved once-daily dosing of lopinavir/ritonavir for treatment-experienced HIV-1 infected adults, on the basis of these trial results.
    • 19 Feb 2010 An analysis of HIV protease inhibitor resistance and adherence has been reported at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top